GTBP Historical Cash Flow
| GTBP Stock | USD 3.04 0.36 13.43% |
Analysis of GT Biopharma cash flow over time is an excellent tool to project GT Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 1.9 M or Change To Inventory of 0.0 as it is a great indicator of GT Biopharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining GT Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GT Biopharma is a good buy for the upcoming year.
GTBP |
About GTBP Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in GTBP balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which GTBP's non-liquid assets can be easily converted into cash.
GT Biopharma Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from GT Biopharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Investments are relatively stable compared to the past year. As of 12/11/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, though Other Non Cash Items is likely to grow to (5 M).
GT Biopharma cash flow statement Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (32K) | 5.3M | 3.7M | (3.3M) | (4.6M) | (4.4M) | |
| Free Cash Flow | (3.7M) | (7.3M) | (15.6M) | (15.2M) | (8.9M) | (8.4M) | |
| Other Non Cash Items | 1.6M | 18.4M | 538K | 10K | (5.3M) | (5.0M) | |
| Total Cash From Operating Activities | (3.7M) | (7.3M) | (15.6M) | (15.2M) | (8.9M) | (8.4M) | |
| Net Income | (38.6M) | (28.3M) | (58.0M) | (20.9M) | (7.6M) | (8.0M) | |
| End Period Cash Flow | 28K | 5.3M | 9.0M | 5.7M | 1.1M | 1.4M | |
| Change In Working Capital | 2.9M | 2.4M | 7.9M | (2.0M) | 1.8M | 1.9M | |
| Begin Period Cash Flow | 60K | 28K | 5.3M | 9.0M | 5.7M | 6.0M | |
| Other Cashflows From Financing Activities | 2.2M | 12.5M | 41.1M | 12.1M | (2.0M) | (1.9M) | |
| Total Cash From Financing Activities | 3.4M | 12.5M | 42.3M | (224K) | 6.3M | 5.1M | |
| Change To Liabilities | 136K | 3.2M | (838K) | 7.1M | 8.1M | 8.5M | |
| Stock Based Compensation | 5.3M | 269K | 33.9M | 7.6M | 2.2M | 2.1M | |
| Net Borrowings | 10.7M | 3.4M | 12.5M | 1.2M | 1.4M | 1.3M | |
| Change To Operating Activities | (25K) | (216K) | 3.2M | 863K | 992.5K | 534.6K | |
| Change To Netincome | 238.7M | 31.5M | 18.3M | 34.5M | 39.6M | 64.7M | |
| Investments | (36K) | 200K | (23.0M) | 12.1M | 5.0M | 5.3M |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | LLY | Eli Lilly | PairCorr |
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.